TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11716976

Group type: EXPERIMENTAL
Intervention: Smaller amplitude visual and somatosensory stimuli co-varied within a trial
Number of subjects: 58

Group type: COMPARATOR
Intervention: Postural control system with constant weighting of sensory inputs
Number of subjects: 58
Study: 10095691

Group type: EXPERIMENTAL
Intervention: Self-administration of medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-friendly drug leaflets
Number of subjects: 0
Study: 7924772

Group type: EXPERIMENTAL
Intervention: Insulin-treated pregnant women
Number of subjects: 250

Group type: COMPARATOR
Intervention: Normal pregnant women
Number of subjects: 250
Study: 3094403

Group type: COMPARATOR
Intervention: Continuous Positive Pressure Ventilation (CPPV)
Number of subjects: 13

Group type: COMPARATOR
Intervention: High-Frequency Jet Ventilation (HFJV)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination of HFJV with Intermittent Positive Pressure Ventilation (CV)
Number of subjects: 13
Study: 30354781

Group type: EXPERIMENTAL
Intervention: Continued thienopyridine therapy
Number of subjects: 2925
Study: 26663590

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (200 mcg every 12 h)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intravenous oxytocin (starting from 6 mU/min to maximum 40 mU/min)
Number of subjects: 85
Study: 24460033

Group type: EXPERIMENTAL
Intervention: 10% chlorhexidine coating
Number of subjects: 983

Group type: COMPARATOR
Intervention: Placebo coating
Number of subjects: 983
Study: 22979982

Group type: EXPERIMENTAL
Intervention: Amantadine (100 mg twice daily) for 4 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) (500 mg once daily) for 4 weeks
Number of subjects: 52
Study: 20223132

Group type: EXPERIMENTAL
Intervention: Intracapsular anesthesia (8 mL of 2% lidocaine) - Group B
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Oral clorazepate dipotassium (5 mg one hour before biopsy) - Group C
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Local anesthesia and clorazepate - Group D
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 160
Study: 18672400

Group type: EXPERIMENTAL
Intervention: PBT2 250 mg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: PBT2 50 mg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 18389900

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily (in patients not receiving stavudine)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo (in patients not receiving stavudine)
Number of subjects: 130
Study: 15364769

Group type: EXPERIMENTAL
Intervention: Small-bowel feeding
Number of subjects: 74

Group type: COMPARATOR
Intervention: Gastric feeding
Number of subjects: 74
Study: 11524351

Group type: EXPERIMENTAL
Intervention: 5 mL of 2% lidocaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 9 mL of 2% lidocaine
Number of subjects: 50
Study: 9266230

Group type: EXPERIMENTAL
Intervention: Doxazosin (1-4 mg o.d.)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 8395761

Group type: EXPERIMENTAL
Intervention: Captopril, 6.25 mg orally
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Enalapril, 2.5 mg orally
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Perindopril, 2 mg orally
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Enalaprilat, 1.5 mg intravenously
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Perindoprilat, 1.0 mg intravenously
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 3531310

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d. for 6 weeks
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 31095423

Group type: EXPERIMENTAL
Intervention: Hybrid Closed-Loop Control (HCLC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sensor-Augmented Pump (SAP)
Number of subjects: 44
Study: 28721310

Group type: EXPERIMENTAL
Intervention: Usual education plus educational DVD
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual education
Number of subjects: 37
Study: 25461690

Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 2031

Group type: COMPARATOR
Intervention: 24-month DAPT
Number of subjects: 2031
Study: 23914733

Group type: EXPERIMENTAL
Intervention: Combined VR and upper limb conventional (ULC) therapy
Number of subjects: 376

Group type: COMPARATOR
Intervention: ULC therapy alone
Number of subjects: 376
Study: 21298358

Group type: EXPERIMENTAL
Intervention: 8.4% sodium bicarbonate
Number of subjects: 11

Group type: COMPARATOR
Intervention: 5% sodium chloride
Number of subjects: 11
Study: 19196038

Group type: EXPERIMENTAL
Intervention: Novel electric breast pump (Embrace, Playtex, Westport, CT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard electric breast pump (Pump In Style, Medela, Baar, Switzerland)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both pumps
Number of subjects: 62
Study: 16952209

Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen treatment
Number of subjects: 83

Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 83
Study: 14610236

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF, filgrastim) 300 microg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg (oral) before G-CSF injection
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study: 11391341

Group type: EXPERIMENTAL
Intervention: Recombinant granulocyte colony-stimulating factor (rG‐CSF)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control subjects (no rG‐CSF)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Recombinant granulocyte colony-stimulating factor (rG‐CSF) in subgroups '<2000 g' or 'neutropenia'
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Recombinant granulocyte colony-stimulating factor (rG‐CSF) excluding non-randomized studies
Number of subjects: 155
Study: 9257069

Group type: EXPERIMENTAL
Intervention: Quality of life assessment in comparative cancer trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survival duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient functioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient well-being
Number of subjects: 0
Study: 8280188

Group type: EXPERIMENTAL
Intervention: Exercise (E, n = 39)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Diet (D, n = 40)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Diet plus Exercise (DE, n = 39)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control (C, n = 39)
Number of subjects: 157
Study: 2426590

Group type: EXPERIMENTAL
Intervention: Intravenous gamma globulin plus aspirin
Number of subjects: 153

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 153
Study: 30451186

Group type: EXPERIMENTAL
Intervention: 3D viewing system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional microscope
Number of subjects: 50
Study: 26926419

Group type: EXPERIMENTAL
Intervention: Multimodal drug injection
Number of subjects: 62

Group type: COMPARATOR
Intervention: No multimodal drug injection (control group)
Number of subjects: 62
Study: 25144794

Group type: EXPERIMENTAL
Intervention: TB treatment
Number of subjects: 191
Study: 22760303

Group type: EXPERIMENTAL
Intervention: 0.93 GBq (25 mCi) of iodine-131
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: 1.85 GBq (50 mCi) of iodine-131
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: 3.7 GBq (100 mCi) of iodine-131
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Overall (all groups combined)
Number of subjects: 422

Group type: COMPARATOR
Intervention: 0.93 GBq (25 mCi)
Number of subjects: 422

Group type: COMPARATOR
Intervention: 1.85 GBq (50 mCi)
Number of subjects: 422
Study: 20649979

Group type: EXPERIMENTAL
Intervention: Highly diluted homeopathic drug (potency C12 = 1024), Dose: 5 globules taken 5 times per day over a maximum period of 5 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (sucrose globules)
Number of subjects: 30
Study: 18083454

Group type: EXPERIMENTAL
Intervention: Video games promoting health-related behavior change
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Video games with immersive stories and interactivity
Number of subjects: 27
Study: 15883353

Group type: EXPERIMENTAL
Intervention: Bisection test in severe unilateral neglect group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bisection test in group without unilateral neglect
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bisection test in controls
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Rebisection test in severe unilateral neglect group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Rebisection test in group without unilateral neglect
Number of subjects: 41

Group type: COMPARATOR
Intervention: Rebisection test in controls
Number of subjects: 41
Study: 12021219

Group type: EXPERIMENTAL
Intervention: Abciximab in patients with ACS
Number of subjects: 4809

Group type: EXPERIMENTAL
Intervention: Tirofiban in patients without ACS
Number of subjects: 4809

Group type: COMPARATOR
Intervention: Tirofiban in patients with stable coronary syndromes
Number of subjects: 4809
Study: 9857536

Group type: EXPERIMENTAL
Intervention: Blood platelets count, mean blood platelet volume, platelocrit, volume range of blood platelets, coagulation time by Duke's method.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Concentration of beta‐thromboglobulin (beta‐TG) and platelet factor‐4 (PF‐4) in plasma by ELISA method.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Aggregation of blood platelets under the influence of ADP according to Born's method.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Beta‐TG and PF‐4 standardized based on blood platelets count.
Number of subjects: 45
Study: 7826080

Group type: EXPERIMENTAL
Intervention: KW-2307 (KW) 25 mg/m2
Number of subjects: 154

Group type: COMPARATOR
Intervention: Vindesine (VDS) 3 mg/m2
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: KW-2307 (KW) with cisplatin (CDDP) 80 mg/m2
Number of subjects: 154

Group type: COMPARATOR
Intervention: Vindesine (VDS) with cisplatin (CDDP) 80 mg/m2
Number of subjects: 154
Study: 2223417

Group type: EXPERIMENTAL
Intervention: 100 mg miglitol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 100 mg acarbose
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 155096

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Timolol 1.5%
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30659811

Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard antihypertensive treatment
Number of subjects: 9361
Study: 28118174

Group type: EXPERIMENTAL
Intervention: Fesoterodine therapy (4-8 mg daily, n = 322)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Placebo (n = 323)
Number of subjects: 645
Study: 26023772

Group type: EXPERIMENTAL
Intervention: Chlorhexidine using a syringe
Number of subjects: 101

Group type: COMPARATOR
Intervention: Soapy water using a syringe
Number of subjects: 101

Group type: COMPARATOR
Intervention: Clear water with soap during a daily shower
Number of subjects: 101
Study: 22368214

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22286574

Group type: EXPERIMENTAL
Intervention: 3-piece acrylic hydrophobic IOL (AcrySof, MA3OBA)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1-piece acrylic hydrophobic IOL (AcrySof, SA3OAL)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 3-piece silicone IOL (CeeOn 911A)
Number of subjects: 96

Group type: COMPARATOR
Intervention: 3-piece acrylic hydrophobic IOL (AcrySof, MA3OBA) and 1-piece acrylic hydrophobic IOL (AcrySof, SA3OAL)
Number of subjects: 96

Group type: COMPARATOR
Intervention: All IOL groups
Number of subjects: 96
Study: 20191711

Group type: EXPERIMENTAL
Intervention: Experimental intervention group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 18
Study: 17076980

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl 3.8 g/day plus ezetimibe 10 mg/day
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ezetimibe monotherapy
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl plus ezetimibe
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 86
Study: 15555723

Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid drink (TFD)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 13
Study: 11414672

Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 15
Study: 9540024

Group type: EXPERIMENTAL
Intervention: Miglitol (50, 100, 150, 200 mg t.i.d.)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study: 7972294

Group type: EXPERIMENTAL
Intervention: Regular instant coffee
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intermittent regime (2 days decaff, 1 day caff)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Caffeine abstinence (general)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Caffeine treatment (overall)
Number of subjects: 120
Study: 2585731

Group type: EXPERIMENTAL
Intervention: Second trial intervention based on LDH as a prognostic factor
Number of subjects: 79

Group type: COMPARATOR
Intervention: First trial intervention
Number of subjects: 79
Study: 1096904

Group type: EXPERIMENTAL
Intervention: Indometacin (100 g/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Indometacin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 27
Study: 31145798

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 1859

Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 1859

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1859

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1859
Study: 29595683

Group type: EXPERIMENTAL
Intervention: Specific tactile input (STI) stimuli according to the Vojta protocol (STI-group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-STI stimulation (non-STI-group)
Number of subjects: 16
Study: 26242289

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 122

Group type: COMPARATOR
Intervention: Moderately fat-reduced diet
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 122
Study: 25291960

Group type: EXPERIMENTAL
Intervention: Sit-stand workstation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 42
Study: 22228279

Group type: EXPERIMENTAL
Intervention: Provocative discography plus intradiscal injection of dexamethasone (5 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intridiscal injection of saline (placebo)
Number of subjects: 45
Study: 20084586

Group type: EXPERIMENTAL
Intervention: New method of surfactant application
Number of subjects: 1541

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1541
Study: 17622942

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (Copaxone) immunotherapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15683662

Group type: EXPERIMENTAL
Intervention: External beam irradiation (EBI) 6 MV photons, total dose 24 Gy in six fractions in 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no radiation therapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: External beam irradiation (EBI)
Number of subjects: 60
Study: 12095383

Group type: EXPERIMENTAL
Intervention: Nevirapine (200 mg oral dose to women after onset of labor and 2 mg/kg oral dose to newborns between 48 and 72 hours after birth)
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1270
Study: 10073610

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) with atherosclerotic disease
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 80
Study: 8700767

Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement restoration (Ketac-Fil)
Number of subjects: 25
Study: 2029180

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 6778337

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adenoidectomy with concomitant myringotomy and tympanostomy tube insertion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 6607027

Group type: EXPERIMENTAL
Intervention: Rifampin-trimethoprim (3.75:1)
Number of subjects: 747

Group type: COMPARATOR
Intervention: Rifampin alone
Number of subjects: 747
Study: 31474119

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (6 messages per week for 6 months)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 502

Group type: COMPARATOR
Intervention: Control group (usual care + 2 thank you messages per month)
Number of subjects: 502
Study: 29700104

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 21

Group type: COMPARATOR
Intervention: Subtherapeutic CPAP
Number of subjects: 21
Study: 27755050

Group type: EXPERIMENTAL
Intervention: Wound support network (n = 32)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard organization of treatment (n = 21)
Number of subjects: 53
Study: 24448006

Group type: EXPERIMENTAL
Intervention: Aerobic bench stepping with arm movements
Number of subjects: 32

Group type: COMPARATOR
Intervention: Aerobic bench stepping without arm movements
Number of subjects: 32
Study: 22832540

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 23
Study: 19779025

Group type: EXPERIMENTAL
Intervention: Olanzapine orally disintegrating tablets (ODT) 10 mg o.d. for 8 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Olanzapine standard oral tablets (OST) 10 mg o.d. for 8 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 10
Study: 17687152

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg orally every morning for 7 days
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo orally every morning for 7 days
Number of subjects: 142
Study: 16326662

Group type: EXPERIMENTAL
Intervention: STAR‐C training
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study: 14601011

Group type: EXPERIMENTAL
Intervention: Markov chain model of Lakatos
Number of subjects: 0
Study: 10673975

Group type: EXPERIMENTAL
Intervention: Remission-induction therapy followed by one consolidation course, with randomisation between autologous bone marrow transplantation (ABMT) and a second intensive consolidation course.
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (alloBMT) for patients with a histocompatible sibling donor.
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Full protocol treatment completion.
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Overall survival rate at 6 years from diagnosis.
Number of subjects: 676
Study: 8608488

Group type: EXPERIMENTAL
Intervention: Granisetron (GRA) 3 mg i.v.
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Ondansetron (OND) 24 mg i.v.
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Tropisetron (TRO) 5 mg i.v.
Number of subjects: 117
Study: 2012289

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 0.75 ml.kg‐1 with morphine 0.05 mg.kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.25% bupivacaine 0.75 ml.kg‐1
Number of subjects: 30
Study: 6128270

Group type: EXPERIMENTAL
Intervention: 0.5 mg of 16-phenoxy-omega-17,18,19,20-tetranor-PGE2 methyl sulphonylamide
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 1.0 mg of 16-phenoxy-omega-17,18,19,20-tetranor-PGE2 methyl sulphonylamide
Number of subjects: 295
Study: 31535560

Group type: EXPERIMENTAL
Intervention: advance care planning (survey, goals of care conversation, advance directive)
Number of subjects: 85

Group type: COMPARATOR
Intervention: control (developmental history, safety tips, nutrition/exercise)
Number of subjects: 85
Study: 31383503

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) program (20 weeks, 3 sessions/week, 4-8 exercises using free weights)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control obesity (CO) group
Number of subjects: 21
Study: 27044282

Group type: EXPERIMENTAL
Intervention: Planned invasive treatment
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Planned conservative treatment
Number of subjects: 1232
Study: 25887557

Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23376318

Group type: EXPERIMENTAL
Intervention: Corticosteroid injections (4 quadrant injections of 0.5 mL triamcinolone, 40 mg/mL, n = 29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (controls, n = 31)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (controls)
Number of subjects: 60
Study: 20675729

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation in addition to conventional medical therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional medical therapy alone
Number of subjects: 100
Study: 19473600

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg administered in a fed state (after a high-fat, high-calorie breakfast)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fesoterodine 8 mg administered in a fasted state
Number of subjects: 16
Study: 18039018

Group type: EXPERIMENTAL
Intervention: Topical terbinafine (various formulations)
Number of subjects: 2899